Sector News

Nicholas Valeriani Appointed To Edwards Lifesciences’ Board Of Directors

November 17, 2014
Life sciences
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee.  Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs.  Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee. 
 
“We are pleased to add Nick’s talents and deep experience to a strong board that is guiding Edwards’ focused innovation strategy, as we develop and deliver important therapies to patients in need,” said Michael A. Mussallem, Edwards’ chairman and CEO. “I’m confident that his long career dedicated to improving patients’ lives provides him with a very informed and contemporary view on both the development of groundbreaking devices and also how best to provide them to patients and physicians in an increasingly complex global healthcare system.”
 
Currently, Valeriani serves on the boards of directors of Robert Wood Johnson University Hospital, the Reagan-Udall Foundation, Reflexion Health, Inc., and the Center for Medical Interoperability.
 
Valeriani has a master’s degree in business administration from Rutgers University, Graduate School of Management, and a bachelor’s degree in industrial engineering from Rutgers University, College of Engineering.
 
Source: Edwards Lifesciences

comments closed

Related News

May 4, 2024

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio

Life sciences

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.

May 4, 2024

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Life sciences

The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.

May 4, 2024

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Life sciences

Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.

How can we help you?

We're easy to reach